Immune Therapeutics, Inc. (IMUN) financial statements (2021 and earlier)

Company profile

Business Address 37 NORTH ORANGE AVENUE
ORLANDO, FL 32801
State of Incorp. FL
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 00000
Cash and cash equivalents 00000
Receivables    0 
Inventory, net of allowances, customer advances and progress billings 00   
Inventory 00   
Other undisclosed current assets     0
Total current assets: 00000
Noncurrent Assets
Property, plant and equipment 00000
Intangible assets, net (including goodwill)    (2)6
Intangible assets, net (excluding goodwill)    (2)6
Deposits noncurrent assets     0
Other undisclosed noncurrent assets 0002 
Total noncurrent assets: 00006
TOTAL ASSETS: 00006
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 55531
Accounts payable 22222
Accrued liabilities 32311
Other undisclosed accounts payable and accrued liabilities     (2)
Debt 5543 
Derivative instruments and hedges, liabilities 1    
Other undisclosed current liabilities  2  2
Total current liabilities: 1111963
Noncurrent Liabilities
Long-term debt and lease obligation     0
Long-term debt, excluding current maturities     0
Total noncurrent liabilities:     0
Total liabilities: 1111964
Stockholders' equity
Stockholders' equity attributable to parent, including: (11)(6)(5)(4)2
Common stock 00000
Additional paid in capital 370367360343338
Accumulated deficit (381)(373)(366)(350)(334)
Other undisclosed stockholders' equity attributable to parent 0(0)03(3)
Stockholders' equity attributable to noncontrolling interest  (5)(4)(2)1
Other undisclosed stockholders' equity     (0)
Total stockholders' equity: (11)(11)(9)(6)2
TOTAL LIABILITIES AND EQUITY: 00006

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues 0 00 
Cost of revenue (0)(2)(3) (36)
Cost of goods and services sold (0)(2)(3)  
Gross profit: 0(2)(3)0(36)
Operating expenses (4)(6)(14)(16)(9)
Other undisclosed operating income  23  
Operating loss: (4)(6)(14)(16)(45)
Nonoperating expense (5)(2)(6)(1)(5)
Investment income, nonoperating (3)    
Interest and debt expense (1)1(0)(1)(5)
Loss before gain (loss) on sale of properties: (9)(7)(20)(18)(55)
Other undisclosed net income 1   5
Net loss: (9)(7)(20)(18)(50)
Net income attributable to noncontrolling interest 0   2
Other undisclosed net income (loss) attributable to parent  (1)01(2)
Net loss attributable to parent: (8)(8)(20)(17)(50)
Other undisclosed net income available to common stockholders, basic  1032
Net loss available to common stockholders, diluted: (8)(7)(20)(14)(48)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss: (9)(7)(20)(18)(50)
Comprehensive loss: (9)(7)(20)(18)(50)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest 0   (2)
Comprehensive loss, net of tax, attributable to parent: (8)(7)(20)(18)(52)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: